New imaging showdown: can PSMA PET/CT beat MRI for prostate cancer detection?

NCT ID NCT07533344

Completed Diagnosis Sponsor: Fatih Sultan Mehmet Training and Research Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 60 men who had a prostate biopsy to check for cancer. It compared two imaging methods used to guide the biopsy: the standard multiparametric MRI and a newer scan called Ga-68 PSMA PET/CT. The goal was to see which method better finds aggressive prostate cancers. The results could help doctors choose the best imaging tool for biopsy guidance.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ga-68 PSMA (a radioactive tracer used in PET/CT imaging)
What this could lead to: If PSMA PET/CT proves better than MRI at guiding biopsies, it could become a new standard for detecting aggressive prostate cancers more accurately.
What could go wrong: This is a small, retrospective study (60 patients) that only compares imaging methods, not a treatment trial. Results may not apply to all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Fatih Sultan Mehmet Training and Research Hospital

Istanbul, Istanbul, 34752, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.